Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification
Authors' conclusion
Classification of OTC and FTC into 3 subcategories as defined by the 2022 WHO Classification substantially improves discrimination between low-, intermediate-, and high-risk patients, especially for DSS and RAI-refractory disease.
Study context
- Population
- Adults with oncocytic (OTC) or follicular thyroid carcinoma (FTC) treated at Erasmus MC, the Netherlands, 2000–201652 OTC, 89 FTC
- Exposure
- 2022 vs 2004 WHO Classification of OTC and FTC
- Outcome
- DSS by 2022 WHO Classification, OTC
- Follow-up
- 10 years
Methodological detailssingle-centre, pathology revision by 2 independent pathologists
- Single-centre
- Pathology revision by 2 independent pathologists
Main finding
As reported in the abstract
- Reclassified as EA: OTC
- 15 (28.8%)
- Reclassified as EA: FTC
- 34 (38.2%)
Observational data: associations, not effects.
Further findings
| Outcome | MIOTC | WIOTC |
|---|---|---|
| 10-year DSS by 2004 WHO Classification, OTC | 100% | 64.2% |
FTC and radioactive iodine (RAI)-refractory disease
- Similar trends observed
Original publication
Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification. J Clin Endocrinol Metab. Published 21 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →